

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4255658

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	ASTRAZENECA UK LIMITED	12/22/2016
RECEIVING PARTY DATA		
Name:	ASTRAZENECA AB	
Street Address:	SE-151 85	
City:	SODERTALJE	
State/Country:	SWEDEN	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	15360332
CORRESPONDENCE DATA		
Fax Number:	(301)576-6932	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	301-398-3199	
Email:	IPdocketing@MedImmune.com	
Correspondent Name:	MEDIMMUNE, INC.	
Address Line 1:	ONE MEDIMMUNE WAY	
Address Line 4:	GAITHERSBURG, MARYLAND 20878	
ATTORNEY DOCKET NUMBER:	200383-US-NP	
NAME OF SUBMITTER:	DENISE COOPER	
SIGNATURE:	/Denise Cooper/	
DATE SIGNED:	02/02/2017	
Total Attachments: 3		
source=200383 WW Assignment company#page1.tif		
source=200383 WW Assignment company#page2.tif		
source=200383 WW Assignment company#page3.tif		

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the ~~22 December 2016~~ (the "Effective Date") by and between

ASTRAZENECA UK LIMITED, a company incorporated in England and Wales with registered office address at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA, United Kingdom ("Assignor"); and

ASTRAZENECA AB, a company incorporated in Sweden with registered office address at SE-151 85 Södertälje, Sweden ("Assignee").


WHEREAS, Assignor has agreed to assign to Assignee the Assignor's legal right, title and interest in and to the patent applications identified in the attached Schedule (the "Applications") and in and to the inventions and improvements disclosed in such Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. In consideration of payments made by Assignee to Assignor, receipt of which is hereby acknowledged, the Assignor hereby assigns, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely all their legal right, legal title and legal interest in and to the inventions, the Application and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Application and any patents or applications derived therefrom; and the right to file patent applications derived from the Application directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the "Rights"), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignor acknowledges that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignor waives any right of first refusal that they may have for acquiring such Rights.
2. Assignor agrees with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignor agrees with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.
4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the English courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.



Signed for and on behalf of
ASTRAZENECA UK LIMITED
Name: Sally CURRAN
Title: Authorised Signatory

THE SCHEDULE

APPLICATIONS				
AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
200383-AR-NP	Argentina	National	bis-Pyridazine Compounds and Their Use in Treating Cancer	
200383-BS-NP	Bahamas	National	bis-Pyridazine Compounds and Their Use in Treating Cancer	
200383-BO-NP	Bolivia	National	SP-275-2016	25 Nov 2016
200383-ET-NP	Ethiopia	National	bis-Pyridazine Compounds and Their Use in Treating Cancer	25 Nov 2016
200383-GC-NP	GCC	Regional	32441	27 Nov 2016
200383-WO-NP	International	PCT	PCT/EP2016/078899	25 Nov 2016
200383-JM-NP	Jamaica	National	bis-Pyridazine Compounds and Their Use in Treating Cancer	
200383-LB-NP	Lebanon	National	bis-Pyridazine Compounds and Their Use in Treating Cancer	
200383-PK-NP	Pakistan	National	bis-Pyridazine Compounds and Their Use in Treating Cancer	25 Nov 2016
200383-TW-NP	Taiwan	National	bis-Pyridazine Compounds and Their Use in Treating Cancer	25 Nov 2016
200383-VE-NP	Venezuela	National	bis-Pyridazine Compounds and Their Use in Treating Cancer	